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A Multicenter, Randomized, Placebo- Controlled Trial of 
Atorvastatin for the Primary Prevention of Cardiovascular 
Events in Patients With Rheumatoid Arthritis
George D. Kitas,1 Peter Nightingale,2 Jane Armitage,3 Naveed Sattar,4 Jill J. F. Belch,5 and  
Deborah P. M. Symmons,6 on behalf of the TRACE RA Consortium
Objective. Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of 
statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention 
of CVEs in RA patients.
Methods. A randomized, double- blind, placebo- controlled trial was designed to detect a 32% CVE risk reduction based 
on an estimated 1.6% per annum event rate with 80% power at P < 0.05. RA patients age >50 years or with a disease 
duration of >10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or 
matching placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, transient 
ischemic attack, or any arterial revascularization. Secondary and tertiary end points included plasma lipids and safety.
Results. A total of 3,002 patients (mean age 61 years; 74% female) were followed up for a median of 2.51 years 
(interquartile range [IQR] 1.90, 3.49 years) (7,827 patient- years). The study was terminated early due to a lower than 
expected event rate (0.70% per annum). Of the 1,504 patients receiving atorvastatin, 24 (1.6%) experienced a pri-
mary end point, compared with 36 (2.4%) of the 1,498 receiving placebo (hazard ratio [HR] 0.66 [95% confidence 
interval (95% CI) 0.39, 1.11]; P = 0.115 and adjusted HR 0.60 [95% CI 0.32, 1.15]; P = 0.127). At trial end, patients 
receiving atorvastatin had a mean ± SD low- density lipoprotein (LDL) cholesterol level 0.77 ± 0.04 mmoles/liter lower 
than those receiving placebo (P < 0.0001). C- reactive protein level was also significantly lower in the atorvastatin 
group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). 
CVE risk reduction per mmole/liter reduction in LDL cholesterol was 42% (95% CI −14%, 70%). The rates of adverse 
events in the atorvastatin group (n = 298 [19.8%]) and placebo group (n = 292 [19.5%]) were similar.
Conclusion. Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol lev-
el than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists’ 
Collaboration meta- analysis of statin effects in other populations.
INTRODUCTION
Despite major advances in therapy over the last two de­
cades, rheumatoid arthritis (RA) continues to be associated with 
reduced life expectancy compared to the general population (1). 
Almost half of all deaths in RA (~35–40% of the excess deaths) 
are attributed to cardiovascular disease (CVD) (2). There are many 
mechanisms that may underlie the increased CVD morbidity and 
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mortality in RA, but their cross­ talk and relative contributions are 
not yet fully elucidated. CVD risk factors, including smoking, hyper­
tension, dyslipidemia, increased adiposity, and reduced physical 
activity, are highly prevalent in RA (3) but do not fully account for 
the excess CVD (4). A significant part is attributed to “novel” CVD 
risk factors, such as “high­ grade” inflammation promoting athero­
thrombotic cardiovascular events (CVEs) (4,5). Risk algorithms 
developed for the general population may underestimate CVE risk 
in patients with RA (6–8), even when multipliers are applied, as 
in recently updated European League Against Rheumatism rec­
ommendations (9). This makes identification of RA patients who 
would benefit from primary prevention therapy less precise, leads 
to significant underuse of statins even in patients who fulfill general 
population thresholds for statin treatment (10), and has led some 
to suggest universal prescription of statins in RA (11), as practiced 
in diabetes mellitus (DM).
The efficacy of statins in the primary and secondary preven­
tion of CVEs has been demonstrated in large­ scale trials and meta­ 
analyses (12). CVE reduction is related to the degree of reduction 
of low­ density lipoprotein (LDL) cholesterol levels. Each millimole 
per liter reduction in LDL cholesterol is associated with a 20–22% 
reduction in the risk of myocardial infarction (MI), revascularization, 
and stroke (12). In RA, high­ grade inflammation is associated with 
suppression of total cholesterol, LDL cholesterol, and high­ density 
lipoprotein (HDL) cholesterol levels, as well as changes in lipid struc­
ture and function, promoting atherosclerosis (13,14). The potential 
pleiotropic antiinflammatory/immunomodulatory effects of statins 
(15) may therefore be more relevant in RA than in the general pop­
ulation. In the Trial of Atorvastatin in Rheumatoid Arthritis (TARA), 
atorvastatin 40 mg daily, as an adjunct to disease­ modifying anti­
rheumatic drug (DMARD) therapy, provided a modest additional 
benefit for control of inflammation in RA, at least in a subgroup of 
patients (16), while the Tayside controlled study of rosuvastatin in 
RA suggested a potentially beneficial effect on C­ reactive protein 
(CRP) levels (17). The extent to which statins affect lipid levels and 
reduce CVEs in RA remains uncertain, due to the small number of 
RA patients included in general population trials (18).
The lack of robust primary prevention data, coupled with the 
multifaceted pharmacologic potential of statins in RA suspected 
at that time, prompted the Trial of Atorvastatin for the Primary 
Prevention of Cardiovascular Events in Patients with Rheumatoid 
Arthritis (TRACE RA), the only statin trial with hard CVE end points 
in this population.
PATIENTS AND METHODS
Study design. TRACE RA was a multicenter, randomized, 
double­ blind, placebo­ controlled trial comparing atorvastatin 
40 mg once daily (supplied by Pfizer UK) with placebo (dummy 
atorvastatin) for the primary prevention of CVEs in patients with 
RA. The trial was conducted in 102 rheumatology units in the 
UK, approved by the Southampton and South West Hampshire 
 Multicentre Research Ethics Committee (Ref. No 06/Q1704/171), 
and registered with International Standard Randomised Controlled 
Trial Number 41829447. The final protocol is available at https ://
www.staff net.manch ester.ac.uk/rbe/ethics­integ rity/clini cal­trial s/
portf olio/trace ra/ and in Supplementary Methods 1, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40892/ abstract. See Appendix A for study 
centers and members of the TRACE RA Consortium.
Participants. Patients were eligible if they fulfilled the Amer­
ican College of Rheumatology 1987 criteria for RA (19), were >50 
years of age or had an RA disease duration of >10 years, and 
gave informed consent. Patients taking statins and those with 
known CVD requiring statins, DM, myopathy, or other contrain­
dications to statins were excluded (see Supplementary Methods 
1). Recruiting centers continued their routine practice for screen­
ing (or not) for cardiovascular risk. There were no restrictions with 
regard to RA treatment prior to or during the trial period, other 
than the requirement that patients receive stable doses of anti­
rheumatic medication for the 3 months prior to inclusion in the 
study. Potentially eligible patients were identified during routine 
clinical visits, given the patient information sheet, and invited to 
contact the local trial team if they were interested in participat­
ing. A screening visit was then arranged. All patients recruited 
 provided written informed consent.
Randomization and masking. Trial medication was pro­
vided by Pfizer UK, bottled by an independent pharmaceutical 
company (Catalent Pharma Solutions UK) to good manufacturing 
practice standards, and dispensed by the local study pharmacist. 
The randomization process was incorporated into the drug label­
ing. Center was the only stratifying variable. Catalent performed the 
randomization, labeled each bottle with a unique number, and sup­
plied the packaged drugs to hospital pharmacies with scratch cards 
to allow a patient’s treatment allocation to be revealed, if necessary. 
On entering the trial, each patient was given a filled and labeled 
bottle, coded with a unique study number, which was used for all 
future supplies for that patient. Study treatment remained double­ 
blind for patients, investigators, and study personnel throughout.
Procedures. The trial comprised 3 stages: 1) a screening 
visit to confirm patient eligibility, secure consent, counsel (ver­
bally and with a leaflet) patients on modifiable cardiovascular risk 
factors, and randomize patients (there was no run­ in period); 
2) a 3­ month visit to check drug tolerability and safety (by liver 
function tests and creatine kinase [CK] level); and 3) an intended 
minimum 5­ year treatment period. At the screening visit, base­
line information on demographic characteristics, medical history, 
family history of premature CVD, smoking status, and concom­
itant medication was obtained through interview and case note 
review. The presence of hypertension was assessed by the case 
report form question, “Is the patient known to have hypertension?” 
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Height, weight, and waist circumference were measured. RA dis­
ease activity, severity (physical function), and quality of life were 
assessed using the Disease Activity Score in 28 joints (DAS28) 
(20), the UK version of the Health Assessment Questionnaire 
(HAQ) (21) disability index (DI), and the EuroQol 5­ domain (EQ­ 
5D) instrument (22), respectively. Blood samples were collected 
for routine measurements of hematologic features, biochemical 
features, erythrocyte sedimentation rate, CRP, rheumatoid factor, 
and/or anti–cyclic citrullinated peptide antibodies.
The protocol did not require measurement of lipid levels at 
baseline. The results of any lipid measurements that had been 
requested routinely in primary or secondary care over the previous 
12 months were recorded in the clinical trial record. If there was 
more than 1 lipid measurement, the most recent was used. Gen­
eral practitioners (GPs) were informed if patients were found to 
have hypertension, DM, or an existing indication for statins (e.g., 
known hyperlipidemia, DM, or previously known high CVD risk 
[according to standard guidelines] requiring a statin for primary or 
secondary prevention).
Randomized patients were followed up at 3 and 6 months 
and every 6 months thereafter in person or by telephone. Infor­
mation on trial efficacy and safety end points, disease activity, 
severity, and concomitant medication was collected at each 
visit. Patients were asked if they had taken “most,” “some,” or 
“none” of their tablets. Patients were considered compliant if they 
reported taking “most” of their study tablets since their last visit. 
Study drug administration could be paused, if necessary, for up to 
4 weeks without violating the protocol. Patients who experienced 
a validated primary end point had no further trial visits but were 
followed up for mortality via linkage with national death registers. 
Secondary prevention in these patients was decided by the GP 
and/or treating physician. Patients who were withdrawn from the 
study for reasons other than a primary end point continued to 
attend follow­ up visits to facilitate adverse event and clinical end 
point data collection. Patients who developed a clinical need for a 
statin, other than a primary end point, after randomization could 
be prescribed up to 40 mg of atorvastatin in addition to the ran­
domized trial medication and remain in the trial.
Outcome measures. The prespecified primary end point 
was “major vascular events,” defined as nonfatal MI, nonfatal pre­
sumed ischemic stroke, transient ischemic attack (TIA), any cor­
onary or non­ coronary revascularization, or cardiovascular death, 
excluding both confirmed cerebral hemorrhage (International Sta­
tistical Classification of Diseases and Related Health Problems, 
Tenth Revision [ICD­ 10] codes I64–I99) (23) and non­ coronary 
cardiac death (ICD­ 10 codes I00–I15 and I26–I52), occurring dur­
ing the scheduled treatment period. Secondary end points were 
the separate components of the primary end point. Tertiary end 
points included total and cause­ specific mortality (coronary, other 
vascular, and nonvascular death separately); hospitalizations; 
statin safety­ related outcomes (persistent elevation of alanine 
transaminase [ALT] or aspartate transaminase [AST] or myopathy 
[muscle symptoms plus CK >10× the upper limit of normal (ULN)]; 
and between­ group differences at study end in lipid levels and 
health­ related outcomes (physical function and quality of life).
Additional information about all potential primary end points 
was collected from medical records, death certificates, and post­
mortem examinations (where available). An independent trial 
end points committee reviewed such information on all potential 
CVEs and deaths and classified them according to prespecified 
criteria (see Supplementary Methods 1). Information about hos­
pital admissions was ascertained via linkage, using each patient’s 
unique National Health Service number, with the Health and Social 
Care Information Centre (HSCIC) for England and Wales and the 
Scottish Office’s Information and Statistics Division (ISD), and the 
local hospital medical records departments. Information on mor­
tality and cause of death was obtained via linkage with the HSCIC 
and ISD. Patients were asked at each visit about adverse events 
including muscle pain, and ALT, AST, and CK were measured at 3 
months. Liver function tests were also performed regularly (usually 
every 2–3 months) as part of routine DMARD monitoring. At the 
final study visit, patients were asked to provide a blood sample for 
lipid and CRP analysis. These samples were shipped to a single 
laboratory and measured, blinded with regard to treatment group, 
on an automated validated platform (c311; Roche Diagnostics) 
using the manufacturer’s calibrators and quality control material. 
Between­ run coefficients of variation were all <5.2%. LDL choles­
terol level was estimated using the Friedewald equation (24).
Statistical analysis. The original protocol (Supplementary 
Methods 2, available on the Arthritis & Rheumatology web site 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.40892/ abstract) 
anticipated that a trial of 3,800 patients followed up for 5 years 
would have sufficient statistical power to detect plausible risk 
reduction with atorvastatin. However, a lower than expected 
event rate led to a protocol amendment (Supplementary Methods 
3, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40892/ abstract). The final 
protocol specified a sample size of 5,400, which would have had 
80% power to detect a 32% relative risk reduction in the primary 
end point in the atorvastatin versus placebo arms based on 434 
primary events (Supplementary Methods 1 and Supplementary 
Figure 1, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.40892/ abstract). 
However, the ongoing much lower­ than­ anticipated CVE rate led 
to premature termination of the trial.
All randomized patients were included in the analysis up to 
December 20, 2012 or the end of trial visit, whichever was ear­
lier, irrespective of whether the study drug was continued (i.e., 
intent­ to­ treat analyses). Cox regression models were devel­
oped for time to occurrence of a first CVE using treatment allo­
cation as the independent variable. The models were stratified 
by center and adjusted for baseline imbalances, compliance, 
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and nonstudy statin use (the latter two as time­ dependent vari­
ables using a previously described method [25]). All adjustments 
were prespecified in the protocol and the statistical analysis plan 
(Supplementary Methods 4, available on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40892/ abstract). Treatment differences were expressed as 
hazard ratios (HRs) with 95% confidence intervals (95% CIs). 
P values less than 0.05 (2­ sided) were considered significant. 
Kaplan­ Meier product­ limit estimates of the survival curves were 
calculated. Lipid levels and levels of blood tests monitoring stat in 
safety were compared between groups using Mann­ Whitney 
tests. All analyses were performed with SPSS Statistics for Win­
dows, version 22.0 (IBM).
RESULTS
Trial progress. Between August 7, 2007 and Novem­
ber 21, 2011, 3,002 patients with RA from 102 centers were 
randomized (1,504 to receive atorvastatin and 1,498 to receive 
placebo). Their mean age was 61 years (228 [7.6%] of 3,002 
patients were <50 years of age), and 74% were women. They 
were followed up for a median of 2.51 years (interquartile range 
[IQR] 1.90, 3.49 years), providing 7,827 person­ years of fol­
low­ up. At the time of trial closure (December 31, 2011), the 
observed event rate in the 2 arms combined was 0.70% per 
annum compared with the expected 1.6% per annum. Trial prog­
ress is shown in Figure 1 and Supplementary Table 1, available 
Figure 1. Trial profile. A total of 3,002 patients from 102 UK rheumatology centers were randomized in the Trial of Atorvastatin for the Primary 
Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis (TRACE RA). Of those, 1,504 were randomized to receive atorvastatin 
40 mg daily and 1,498 were randomized to receive matching placebo. A detailed breakdown of follow­ up during the course of the trial is shown 
in Supplementary Table 1, available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40892/ abstract. 
All randomized patients were included in the intent­ to­ treat analysis for the primary and secondary end points. Variable numbers of patients, 
based on data availability, were used for analyses of other outcomes.
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Table 1. Baseline characteristics of the patients randomized to receive atorvastatin or placebo*
Atorvastatin 40 mg 
(n = 1,504)
Placebo 
(n = 1,498)
Demographic/anthropometric characteristics
Sex, female 1,107/1,504 (74) 1,120/1,498 (75)
Age, mean ± SD years (n) 61.1 ± 8.3 (1,500) 60.9 (8.5) (1491)
Race, white 1,394/1,421 (98) 1,407/1,430 (98)
BMI, median (IQR) (n) 26.4 (23.7, 30.1) (1,466) 26.8 (24.0, 30.1) (1,432)
RA characteristics
Time since symptom onset, median (IQR) years (n) 13 (6, 21) (1,471) 13 (6, 21) (1,460)
Time since diagnosis, median (IQR) years (n) 11 (4, 18) (1,499) 11 (5, 20) (1,489)
RF and/or ACPA positive 737/1,177 (63) 709/1,153 (62)
DAS28, median (IQR) (n) 3.7 (2.6, 4.7) (1,471) 3.5 (2.5, 4.6) (1,471)
HAQ DI score, median (IQR) (n) 1.25 (0.50, 1.88) (1,473) 1.25 (0.38, 1.88) (1,464)
EQ- 5D, median (IQR) (n) 0.62 (0.52, 0.80) (1,422) 0.689 (0.52, 0.80) (1,408)
Treatment
Biologic DMARDs 229/1,466 (16) 232/1,458 (16)
Conventional synthetic DMARDs 1,264/1,466 (86) 1,241/1,458 (85)
Steroids 253/1,466 (17) 241/1,458 (17)
NSAIDs/coxibs 629/1,466 (43) 554/1,458 (38)
Cardiovascular characteristics
Smoking status
Current smoker 260/1,422 (18) 209/1,431 (15)
Ex- smoker 606/1,422 (43) 637/1,431 (45)
Never smoked 556/1,422 (39) 585/1,431 (41)
Hypertension 322/1,456 (22) 335/1,437 (23)
First degree relative with premature CVD 285/1,321 (22) 263/1,304 (20)
Total cholesterol, median (IQR) mmoles/liter (n) 5.4 (4.8, 6.1) (845) 5.3 (4.8, 6.0) (832)
Triglycerides, median (IQR) mmoles/liter (n) 1.26 (0.90, 1.80) (673) 1.30 (0.90, 1.80) (652)
HDL cholesterol, median (IQR) mmoles/liter (n) 1.56 (1.2, 1.90) (719) 1.52 (1.25, 1.85) (700)
LDL cholesterol, median (IQR) mmoles/liter (n) 3.2 (2.7, 3.8) (544) 3.2 (2.7, 3.8) (530)
CRP, median (IQR) mg/liter (n) 5 (3, 11) (780) 5 (3, 12) (776)
Estimated GFR, median (IQR) ml/minute/1.73 m2 (n) 79 (59, 110) (1,124) 79 (58, 111) (1,109)
Treatment
Aspirin 3/116 (3) 3/126 (2)
ACE inhibitors 10/113 (9) 10/127 (8)
Other cardiac drugs 10/113 (9) 10/123 (8)
* The variable number of patients for each characteristic is due to missing data from incomplete case report forms. The 
low number of baseline lipid measurements is because, due to budgetary constraints, the protocol did not require mea-
surement of lipid levels at baseline. In the UK, it is the responsibility of primary care physicians to assess their patients for 
cardiovascular risk and to prescribe statins for primary prevention where indicated according to national guidelines. The 
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis (TRACE RA) 
aimed to recruit patients who did not have cardiovascular disease (CVD) at baseline and who were not already taking a 
statin for primary prevention. If lipid levels had been measured routinely in the 12 months prior to recruitment (in prima-
ry or secondary care), the results were recorded in the trial case report form. Except where indicated otherwise, values 
are the number of patients/number for whom data were available (%). BMI = body mass index; IQR = interquartile range; 
RA = rheumatoid arthritis; RF = rheumatoid factor; ACPA = anti–citrullinated protein antibody; DAS28 = Disease Activity 
Score in 28 joints; HAQ DI = Health Assessment Questionnaire disability index; EQ- 5D = EuroQol 5- domain; DMARDs = 
disease- modifying antirheumatic drugs; NSAIDs = nonsteroidal antiinflammatory drugs; HDL = high- density lipoprotein; 
LDL = low- density lipoprotein; CRP = C- reactive protein; GFR = glomerular filtration rate; ACE = angiotensin- converting 
enzyme. 
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on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40892/ abstract.
Baseline characteristics of the patients. At base­
line, the randomized groups were well balanced for all 
demographic, anthropometric, and RA characteristics, anti­
rheumatic and other therapies, and CVD risk factors, except 
for current smoking and nonsteroidal antiinflammatory drug 
(NSAID) or cyclooxygenase 2 inhibitor (coxib) treatment, which 
were higher in the atorvastatin group than in the placebo group 
(18.4% versus 14.5% for current smoking and 42.9% versus 
38.0% for NSAID or coxib treatment). A total of 40.3% of the 
patients had low disease activity according to the DAS28 or 
were in remission (DAS28 ≤3.2), 86% were receiving stable 
doses of conventional synthetic DMARDs, 16% were receiv­
ing biologic DMARDs, and 17% were receiving steroid therapy 
(Table 1 and Supplementary Table 2, available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40892/ abstract).
Compliance and nonstudy statin use. In the atorva­
statin group, reported compliance fell from 89% at the 3­ month 
visit to 39% by 60 months of follow­ up, while nonstudy statin 
use increased from 0.5% to 5.6%. In the placebo group, com­
pliance fell from 89% to 25% and nonstudy statin use increased 
from 0.7% to 7.8% (Supplementary Table 3, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40892/ abstract). Time­ weighted average 
compliance was 66% in the atorvastatin arm and 65% in the 
placebo arm. Time­ weighted nonstudy statin use was 1.6% in 
the atorvastatin arm and 3.3% in the placebo arm.
Primary end point. Twenty­ four patients allocated to 
receive atorvastatin (1.6%) had a confirmed CVE, compared to 
36 (2.4%) of the patients allocated to receive placebo (HR 0.66 
[95% CI 0.39, 1.11]; P = 0.115). After adjustment for baseline dif­
ferences, compliance, and nonstudy statin use, the HR was 0.60 
(95% CI 0.32, 1.15) (P = 0.127). Based on the number of events, 
the numbers of patients, and the mean follow­ up time in each 
arm, the number needed to treat to prevent 1 CVE during the trial 
was 121. Kaplan­ Meier analysis of time to primary end point in 
the 2 groups is shown in Figure 2, and the cumulative incidence 
of first CVE in the 2 groups is shown in Figure 3. The estimated 
reduction in CVE risk per 1 mmole/liter reduction in LDL choles­
terol level was 42% (95% CI −14%, 70%) (Supplementary Figure 
2, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40892/ abstract). This was 
calculated by extrapolating the HR of 0.66 for a 0.77 mmoles/liter 
reduction to an HR of 0.66 to the power of (1/0.77) for a 1 mmole/
liter reduction, i.e., an HR of 0.58 or a CVE risk reduction of 42%.
Secondary end points. Individual components of the pri-
mary end point. Coronary events (nonfatal MI, coronary death, or 
coronary revascularization) occurred in 13 (0.9%) of the patients 
in the atorvastatin group versus 23 (1.5%) of the patients in the 
placebo group. Presumed ischemic stroke or TIA occurred in 6 
(0.4%) of the patients in the atorvastatin group versus 12 (0.8%) 
of the patients in the placebo group, and any non­ coronary arte­
rial revascularization occurred in 3 (0.2%) of the patients in the 
atorvastatin group versus 1 (0.1%) of the patients in the placebo 
group. No other cardiovascular death occurred in either group. A 
peripheral atherosclerotic event occurred in 1 (0.1%) of the patients 
in the atorvastatin group and none of the patients in the placebo 
Figure 2. Kaplan­ Meier plots of time to first cardiovascular event (CVE) for patients in the atorvastatin and placebo groups. HR = hazard ratio; 
95% CI = 95% confidence interval.
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group, and suspected coronary heart disease death occurred in 2 
(0.1%) of the patients in the atorvastatin group versus 1 (0.1%) of 
the patients in the placebo group (Supplementary Table 4, availa­
ble on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40892/ abstract).
Total and cause- specific mortality. Total and cause­ specific 
mortality (coronary, other vascular, and nonvascular deaths sep­
arately) did not differ between the 2 arms (25 deaths in the ator­
vastatin arm [1.7%] and 27 deaths in the placebo arm [1.8%]) 
(Supplementary Table 4).
Safety outcomes. There were no suspected unexpected 
serious adverse reactions. There were 298 reported adverse 
events in the atorvastatin arm (19.8%) and 292 in the placebo arm 
(19.5%) (P = 0.854) (Table 2).
Two hundred fourteen (14.2%) of the patients in the ator­
vastatin group versus 223 (14.9%) of the patients in the placebo 
group had ≥1 hospitalization, with an identical median stay of 3 
days (IQR 1, 6 days). There were no differences in the number 
of hospitalizations per patient (P = 0.710 by Kendall’s  tau­ b) or 
in the proportion of patients with ≥1 hospitalization (P  =  0.641 
by Fisher’s exact test) (Supplementary Table 5, avail able on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40892/ abstract).
Life­ threatening but nonfatal serious adverse events (SAEs) 
occurred in 22 patients in the atorvastatin group versus 24 patients 
in the placebo group, while SAEs resulting in death occurred in 19 
and 18 patients, respectively. None were considered to be related 
to trial medication. The randomization code was broken at the site 
in 3 cases in the atorvastatin arm (due to liver cysts with elevated 
ALT level, acute hepatitis, and abnormal findings on liver function 
tests) and 2 cases in the placebo arm (due to high grade lym­
phoma and chest infection), none of which was attributed to trial 
medication.
There were 64 reports of “RA flare” (significant worsening of 
RA symptoms), 29 in the atorvastatin group and 35 in the placebo 
group. There were 249 reports of “new or significant muscle pain,” 
132 in the atorvastatin group versus 117 in the placebo group 
(P = 0.354). Of these, 13 (9 patients in the atorvastatin group versus 
4 patients in the placebo group) had concurrent ALT or AST eleva­
tion of >2× the ULN, which was neither sustained nor considered 
to be related to the trial medication. Three of these patients (2 in 
the atorvastatin group and 1 in the placebo group) were withdrawn 
from the trial by the local principal investigator. None of the patients 
had a CK elevation of >10× the ULN. Two patients (1 in each group) 
had unsustained CK elevations of 3–10× the ULN; neither was 
considered to be due to trial medication. No asymptomatic cases 
of CK elevation were detected either on monitoring per protocol or 
during routine DMARD monitoring. There were no cases of ALT or 
AST elevation of >5× the ULN on per protocol testing, but there 
were 6 cases outside protocol testing (all unsustained and consid­
ered unrelated to trial medication). Overall, there were 159 cases 
of ALT or AST elevation of 2–5× the ULN (90 in the atorvastatin 
group and 69 in the placebo group; P = 0.103), none of which was 
sustained or attributed to trial medication.
Biochemical and arthritis outcomes at the end of the 
trial. At the end of the trial, mean LDL cholesterol levels were 0.77 
mmoles/liter lower among those allocated to receive atorva statin 
compared to those allocated to receive placebo. In the atorvastatin 
group, 54% of the patients were classified as compliant at the end­ 
of­ trial visit. There were no significant differences between groups 
Figure 3. Cumulative incidence of first cardiovascular event (CVE) for patients in the atorvastatin and placebo groups. HR = hazard ratio; 95% 
CI = 95% confidence interval.
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in RA disease activity (DAS28), severity (HAQ DI), or quality of life 
(EQ­ 5D). However, CRP levels were significantly lower in the ator­
vastatin group (median 2.59 mg/liter [IQR 0.94, 6.08]) than in the 
placebo group (median 3.60 mg/liter [IQR 1.47, 7.49]) (P < 0.0001). 
Although levels of CK and ALT (but not AST) were statistically sig­
nificantly higher (by ~12–15%) in the atorvastatin group (Table 3), 
these differences are not considered clinically significant. The num­
ber of cases of myopathy and elevations of liver enzyme levels 
above the normal range were similar in the 2 groups. In the end­ 
of­ trial analysis of the atorvastatin group, lipid, ALT, and CRP levels 
were significantly associated with compliance (data not shown).
DISCUSSION
TRACE RA was designed to assess whether patients with 
RA who were not already receiving statin therapy would ben­
efit from atorvastatin 40 mg daily for the primary prevention of 
CVEs. In this study, the largest ever academically­ led clinical 
trial in RA, >3,000 RA patients were recruited and followed up 
for a median of 2.5 years. The unexpectedly low event rate 
and resulting limited statistical power to detect an effect during 
the planned 5 years of follow up led to premature termination 
of the trial. The best estimate of the “true” reduction in CVEs 
in the atorvastatin versus placebo arm is 34%. Using a 95% 
confidence level we cannot rule out any effect size between a 
61% reduction and an 11% increase. Thus, our results were 
not statistically significant. The observed 34% reduction is 
consistent with the Cholesterol Treatment Trialists’ Collabora­
tion meta­ analysis of the effect of statins in other populations 
(12). Furthermore, in this potentially vulnerable population, 
atorvastatin was safe, with no excess reports of muscle pain 
or other significant symptoms among those allocated atorva­
statin compared to those receiving placebo.
There were several reasons such a trial was needed. CVD 
remains a major cause of death (5) and is significantly increased 
in people with RA compared to the general population (26), a fact 
recognized by the addition of RA as an independent risk factor in 
CVD risk algorithms such as QRISK2 (27) and QRISK3 (28). The 
relative contribution of classic CVD risk factors and novel mecha­
nisms related to systemic inflammation to the excess CVD mortal­
ity of RA is still debated (4,29,30), and there have been no clinical 
end point trials assessing the effect of statins, or any other primary 
prevention strategy, in this population. Some small studies have 
shown that statins reduce surrogate measures of atheroscle­
rotic events, for example, arterial stiffness (31) or carotid plaque 
(32), while a few cohort studies have suggested that statin use is 
associated with survival gains (33) and statin discontinuation with 
poorer survival (34) in RA. Finally, post hoc analyses of two trials 
of more intensive versus standard statin doses have suggested 
that the effect of statins, in terms of both LDL cholesterol reduc­
tion and CVE prevention, is similar in subjects with “inflammatory 
joint disease,” including RA, and those without joint inflammation; 
however these findings were based on a very small number of 
patients and events (18).
Randomization in TRACE RA was stratified only by study 
site in the expectation that, given the large numbers, baseline 
 variables would distribute evenly between the treatment arms. 
However, baseline current smoking and NSAID/coxib usage, both 
well­ established risk factors for CVEs (35,36), were higher in the 
atorvastatin group. Although every effort was made to maximize 
adherence to the trial medication during the trial, adherence rates 
in TRACE RA were relatively low. Adherence to trial medication in 
statin trials varies widely (37). This appears to depend on many 
factors, including the population studied, whether it is for primary 
or secondary prevention, trial design (e.g. inclusion of a “run­ in” 
period), trial duration, and method of assessing adherence, 
among others. Adherence to statin treatment in real­ world use is 
generally accepted to be <50% (37,38). In this context, the adher­
Table 2. Adverse events according to ICD­ 10 chapter by treatment 
arm*
Atorvastatin 
40 mg 
(n = 1,504)
Placebo 
(n = 1,498)
Infectious and parasitic disease 16 (1.1) 15 (1.0)
Neoplasms 28 (1.9) 30 (2.0)
Blood and blood- forming 
organs and immune system 
disease
5 (0.3) 2 (0.1)
Endocrine, nutritional, and 
metabolic disease
1 (0.1) 1 (0.1)
Mental and behavioral disorder 2 (0.1) 1 (0.1)
Nervous system 4 (0.3) 10 (0.7)
Eye and adnexa 8 (0.5) 5 (0.3)
Ear and mastoid disease 2 (0.1) 0 (0.0)
Circulatory disease 40 (2.7) 45 (3.0)
Respiratory disease 33 (2.2) 38 (2.5)
Digestive system disease 37 (2.5) 28 (1.9)
Skin and subcutaneous system 
disease
12 (0.8) 8 (0.5)
Musculoskeletal and connec-
tive tissue disease
20 (1.3) 22 (1.5)
Genitourinary system disease 13 (0.9) 11 (0.7)
Symptoms, signs, and abnormal 
clinical and laboratory findings 
not classified elsewhere 
8 (0.5) 10 (0.7)
Injury, poisoning 18 (1.2) 16 (1.1)
External causes of morbidity 
and mortality
23 (1.5) 19 (1.3)
None 111 (7.4) 97 (6.5)
Missing 14 (0.9) 14 (0.9)
Any adverse event 298 (19.8) 292 (19.5)
* Values are the number (%) of patients. ICD- 10 = International 
Statistical Classification of Diseases and Related Health Problems, 
Tenth Revision. 
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ence observed in TRACE RA, although disappointing, is probably 
not particularly poor. Prespecified adjusted analyses for baseline 
differences, compliance, and nonstudy statin use resulted in an 
HR of 0.60 (95% CI 0.32, 1.15) (P = 0.127).
From a clinical perspective, the safety outcomes are as 
important as CVE reduction. RA patients typically have multiple 
comorbidities (39) and polypharmacy (40), often with potentially 
hepatotoxic drugs. Virtually all participants in TRACE RA were 
receiving potentially hepatotoxic therapies such as methotrex­
ate, but all patients receiving methotrexate were also prescribed 
folic acid. The 40 mg daily dose of atorvastatin is also of inter­
est, as there are few randomized data on safety for this dose. 
 Reassuringly, the type and severity of adverse events, the rate of 
hospitalizations, elevations of liver or muscle enzyme levels, inci­
dence of myalgia, and worsening of RA were all similar in the 2 
arms. These results suggest that atorvastatin 40 mg (and lower 
doses) is safe to use in patients with RA who are already receiving 
DMARD therapy.
Clinically assessed RA disease activity, severity, and quality 
of life were not significantly different between the 2 groups at the 
end of the trial. However, consistent with data from other studies 
(16,17), levels of CRP were significantly lower, by ~1 mg/liter, in 
the atorvastatin group than in the placebo group. This difference 
is unlikely to be clinically significant in the context of RA disease 
activity.
Since TRACE RA was terminated early because the CVE 
rate was much lower than expected, it is not surprising that 
the HR for the primary end point was not significant. The 
observed number of primary outcomes provides <20% power 
to detect the relative risk reduction of 32% specified in the 
final protocol and provides adequate power (>80%) only to 
detect a relative risk reduction of >68%. The results for the pri­
mary outcome are therefore best represented as the estimated 
HR and its associated confidence interval. When the trial was 
designed (2002–2004), the assumption of a 1.6–1.8% annual 
event rate seemed, if anything, conservative. A meta­ analysis 
of mortality studies in RA published prior to 2005 demon­
strated a meta–standardized mortality ratio of 1.5 (1). Annual 
CVE rates ranged from 2.5–5% (26). Possible explanations for 
the lower­than­expected observed event rate in TRACE RA 
include: 1) event rates in randomized trials are always lower 
than in observational studies and the “healthy volunteer” effect 
may have been more pronounced than usual; 2) TRACE RA, 
by design, excluded patients with the highest baseline CVE 
risk since these patients were already being treated or had a 
recommendation for a statin; 3) TRACE RA participants were 
Table 3. Lipid levels and other outcomes at trial end by treatment arm*
Atorvastatin 40 mg 
(n = 1,504)
Placebo 
(n = 1,498)
Difference (atorvastatin 
minus placebo) P†
Lipid variable, mean ± SEM (n)
Total cholesterol, mmoles/liter 4.13 ± 0.04 (987) 4.86 ± 0.04 (973) −0.72 ± 0.05 <0.0001
Triglycerides, mmoles/liter 1.10 ± 0.02 (987) 1.26 ± 0.03 (973) −0.16 ± 0.03 <0.0001
HDL cholesterol, mmoles/liter 1.41 ± 0.01 (987) 1.30 ± 0.01 (972) 0.11 ± 0.02 <0.0001
LDL cholesterol, mmoles/liter 2.21 ± 0.03 (985) 2.98 ± 0.03 (965) −0.77 ± 0.04 <0.0001
Other variables, median (IQR) (n)
CK, units/liter 94 (69, 135) (986) 84 (60, 118) (971) – <0.0001
CRP, mg/liter 2.59 (0.94, 6.08) (987) 3.60 (1.47, 7.49) (972) – <0.0001
ALT, units/liter 24.0 (17.4, 33.0) (987) 20.8 (15.5, 27.7) (973) – <0.0001
AST, units/liter 36.2 (28.5, 46.7) (987) 35.6 (27.5, 46.6) (973) – 0.185
Clinical outcomes, median (IQR) (n)
EQ- 5D score 0.66 (0.52, 0.80) (1,062) 0.70 (0.52, 0.80) (1,079) – 0.301
HAQ DI score 1.25 (0.38, 1.88) (1,105) 1.25 (0.38, 1.97) (1,124) – 0.644
DAS28 score 3.3 (2.3, 4.4) (997) 3.3 (2.4, 4.4) (1,023) – 0.515
DAS28 category, no./no. available (%) 0.368
High (>5.1) 133/997 (13.3) 129/1,023 (12.6) –
Moderate (>3.2, ≤5.1) 391/997 (39.2) 428/1,023 (41.8) –
Low (>2.6, ≤3.2) 153/997 (15.3) 171/1,023 (16.7) –
Remission (≤2.6) 320/997 (32.1) 295/1,023 (28.8) –
* All patients attending the end- of- trial visit (1,211 per arm) were invited to provide blood samples for measurement of lipid levels and other 
variables. Of these patients, ~83% in each study arm agreed. HDL = high- density lipoprotein; LDL = low- density lipoprotein; IQR = inter-
quartile range; CK = creatine kinase; CRP = C- reactive protein; ALT = alanine transaminase; AST = aspartate transaminase; EQ- 5D = EuroQol 
5- domain; HAQ DI = Health Assessment Questionnaire disability index. 
† By t- test for lipid levels, by Kendall’s tau- b for Disease Activity Score in 28 joints (DAS28) category, and by Mann- Whitney tests for all other 
comparisons. 
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younger than in other statin trials and were predominantly 
female (as expected from RA disease demographics); and 4) 
<20% of participants had high disease activity at baseline.
There is increasing evidence that good disease control 
reduces the progression of subclinical atherosclerosis in RA 
patients (41,42) and is associated with better cardiovascular out­
comes. Therefore, an additional explanation for the low event rate 
observed in TRACE RA might have been a significant increase 
in the use of DMARDs, particularly biologic DMARDs, during the 
course of the trial. However, this was not the case. The use of 
prednisolone (in terms of frequency and average daily dosage), 
conventional synthetic DMARDs, and biologic DMARDs at base­
line was balanced between the atorvastatin and placebo groups 
and remained so during the trial. There was not any significant 
increase in the use of biologic DMARDs during the trial in either 
group (Supplementary Section 1, available on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40892/ abstract). Some recent studies suggest a modest 
decline in CVE rates, mirroring those observed in the general 
population (43,44), while others demonstrate a very substantial 
decline in CVE rates in RA (45). Although it is possible that CVEs 
may have been missed in both the atorvastatin and placebo arms, 
we believe this is unlikely due to the robust CVE capture system 
including regular patient review (80% of the patients attended the 
end­ of­ trial visit in both arms) and linkage with several national 
electronic data sources. Information from data linkage was avail­
able for all patients.
Overall, the findings of TRACE RA have important implications 
for clinical practice and research. The large randomized statin trials 
have shown that statin therapy reduces CVE risk by approximately 
one­ third, regardless of the level of background risk. Neverthe­
less, most guidelines recommend therapy only for those whose 
estimated individual 10­ year or lifetime risk falls above a certain 
threshold, for reasons of cost and risk/benefit ratio (46). TRACE 
RA suggests that contemporary RA patients are likely to derive the 
same level of benefit from statins as other populations. However, 
the low event rate shows that there is a sizeable population of 
RA patients (even among those older than 50 years or with >10 
years of disease duration) who have a relatively low CVD risk. This 
finding does not support prescribing statins to all RA patients, one 
of the main questions addressed by this trial. Instead, the  decision 
to prescribe should be based on assessment of the individual 
RA patient’s risk using, at present, the relevant national or inter­
national recommendations and risk assessment tools (9), while 
disease­ specific algorithms are developed and validated (47). In 
terms of future research, TRACE RA provides information about 
effect and sample sizes that may be helpful in the design of future 
trials investigating CVD prevention strategies in RA, whether these 
are based on cardiovascular interventions, intensive inflammatory 
disease control, or both.
In conclusion, TRACE RA suggests that atorvastatin 40 mg daily 
is safe for the primary prevention of CVEs in patients with RA and 
appears to confer a similar degree of risk reduction in these patients 
as in other populations. CVE rates are decreasing in this population. 
This finding requires further investigation and does not support a pri­
mary prevention strategy involving statin use in all RA patients.
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APPENDIX A: THE TRACE RA CONSORTIUM
For the TRACE RA Consortium, members of the Trial Manage­
ment Committee were as follows: chief investigator, Dr. George 
D. Kitas (University of Manchester and Dudley Group NHS Foun­
dation Trust); lead investigators, Dr. Jill J. F. Belch (University of 
Dundee) and Dr. Deborah P. M. Symmons (University of Man­
chester); trial managers, Dr. Hawys Williams (University of Man­
chester), Mrs. Shobna Vasishta (University of Dundee), and Mrs. 
Rebecca Storey (Dudley Group NHS Foundation Trust); trial stat­
istician, Dr. Peter Nightingale (University Hospitals Birmingham); 
senior investigators, Dr. Ian Bruce (University of Manchester), Dr. 
Paul Durrington (University of Manchester), Dr. Iain McInnes (Uni­
versity of Glasgow), Dr. Naveed Sattar (University of Glasgow), 
Dr. Deva Situnayake (City Hospital, Birmingham), and Dr. Allan 
Struthers (University of Dundee).
Members of the Trial Steering Committee were as follows: 
chairman, Dr. Gordon Lowe (University of Glasgow); independent 
members, Dr. Jane Armitage (University of Oxford), Dr. Keith Fox 
(University of Edinburgh Centre for Cardiovascular Science), and 
Dr. Dorian Haskard (Eric Bywaters Centre for Vascular Inflam­
mation, Imperial College London); Arthritis Research UK mem­
ber, Ms Caroline Dore; lay member, Ms  Ailsa Bosworth (National 
Rheumatoid Arthritis Society), investigators, Dr. George D. Kitas 
(University of Manchester and Dudley Group NHS  Foundation 
Trust), Dr. Jill J. F. Belch (University of Dundee), Dr. Deborah 
P. M. Symmons (University of Manchester), and Dr. Hawys Wil­
liams (University of Manchester).
Members of the Data Monitoring Committee were as follows: 
chairman, Dr. Michael Frenneaux (University of Aberdeen); Dr. 
Christopher Edwards (University of Southampton), Dr. Jonathan 
Emberson (University of Oxford Clinical Service Unit), and Dr. 
Deborah Bax (University of Sheffield).
Members of the Endpoints Committee were as follows: chair­
man, Dr. Stuart Cobbe (University of Glasgow); Dr. David Stott 
(University of Glasgow), Dr. Roger Sturrock (University of Glas­
gow), and Dr. Peter Macfarlane (University of Glasgow).
TRACE RA recruiting centres and principal investigators were 
as follows: Dudley Group of Hospitals NHS Trust (Dr. Rainer 
Klocke), NHS Tayside–Tayside University Hospitals NHS Trust 
(Dr. Tom Pullar and Dr. Su Tan), East Cheshire NHS Trust (Dr. Su­
san Knight), Worcestershire Acute Hospitals NHS Trust (Dr. Iain 
Rowe), NHS Grampian (Dr. Pradeep Kumar), Aintree Hospitals 
NHS Trust (Dr. Nicky Goodson), Mid Staffordshire General Hos­
pitals NHS Trust (Dr. Diarmuid Mulherin), NHS Forth Valley (Dr. 
Micheal Brzeski), Western Health and Social Care Trust (Dr. Philip 
Gardiner), Sandwell and West Birmingham NHS Trust (Dr. Deva 
Situnayake), Newcastle Upon Tyne Hospitals NHS Foundation 
Trust (Dr. David Walker), Aneurin Bevan Health Board (Dr. Rob 
Callaghan), University Hospitals of Coventry and Warwickshire 
NHS Trust (Dr. Margaret Allen), NHS Greater Glasgow & Clyde–
North Glasgow University Hospital Division (Dr. David McCarey), 
Wirral Hospital NHS Trust (Dr. Emmanuel George), Derby Hospi­
tals NHS Foundation Trust (Dr. Chris Deighton), Guy’s & St. Thom­
as’ NHS Foundation Trust (Dr. Bruce Kirkham), East Lancashire 
Hospitals NHS Trust (Dr. Lee­ Suan Teh), Nuffield Orthopaedic 
Centre NHS Trust (Dr. Raashid Luqmani), Barking, Havering and 
Redbridge Hospitals NHS Trust (Dr. Kuntal Chakravarty and Dr. 
Euthalia Roussou), Countess of Chester Hospital NHS Founda­
tion Trust (Dr. Jenny Nixon), Poole Hospital NHS Trust (Dr. Selwyn 
Richards), King’s College Hospital NHS Trust (Dr. David Scott), 
Royal Cornwall Hospitals NHS Trust (Dr. Tony Woolf), Hampshire 
Private Hospitals (Dr. Peter Prouse), University Hospital of North 
Staffordshire NHS Trust (Dr. Jonathan Packham), Pontypridd 
& Rhondda NHS Trust (Dr. Martin Davies), East Kent Hospitals 
NHS Foundation Trust (Dr. Denise DeLord), Salford Royal NHS 
Foundation Trust (Dr. Terence O’Neill), Nottingham University 
Hospitals NHS Trust (Dr. Ira Pande), NHS Highland (Dr. John 
Harvie), Ipswich Hospital NHS Trust (Dr. Richard Watts), Univer­
sity Hospital Birmingham NHS Foundation Trust (Dr. Elizabeth 
Rankin), Brighton and Sussex University Hospitals NHS Trust 
(Dr. George Papasavvas), Leeds Teaching Hospitals NHS Trust 
(Dr. Paul Emery and Dr. Ann Morgan), Heart of England NHS 
Foundation Trust (Dr. Arvind Sinha), Southend Hospital NHS 
Trust (Dr. Bhaskar Dasgupta), Central Manchester & Manchester 
Children’s University Hospitals NHS Trust (Dr. Ian Bruce), North 
Bristol NHS Trust (Dr. Paul Creamer), NHS Lanarkshire–Acute 
Ser vices Division (Dr. Asad Zoma), Sherwood Forest Hospitals 
NHS Trust (Dr. David Walsh), South Tees Hospitals NHS Foun­
dation Trust (Dr. Jaap Van­ Laar), Shrewsbury and Telford Hospi­
tal NHS Trust (Dr. Nigel Capps), Belfast Health and Social Care 
Trust (Dr. Andrew Cairns), South Warwickshire General Hos­
pitals NHS Trust (Dr. Christopher Marguerie), County Durham 
and Darlington Acute Hospitals NHS Trust (Dr. Namita Kumar), 
St. Helens & Knowsley Teaching Hospital NHS Trust (Dr. 
Rikki Abernethy), Hinchingbrooke Healthcare NHS Trust (Dr. Mark 
Lillicrap), NHS Lothian–Lothian University Hospitals Division (Dr. 
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Stuart Ralston), Surrey & Sussex Healthcare (Dr. Raad Makadsi), 
The Royal Bournemouth and Christchurch Hospitals NHS Foun­
dation Trust (Dr. Neil Hopkinson), Sheffield Teaching Hospitals 
NHS Foundation Trust (Dr. Mohammed Akil), North West Wales 
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Thomas), Cambridge University Hospitals NHS Foundation 
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